Sabutoclax

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameSabutoclax
Drug Alias NameONT 701BI-97C1
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionApoptosis regulator Bcl-X inhibitorsApoptosis regulator Bcl-2 inhibitorsInduced myeloid leukemia cell differentiation protein Mcl-1 inhibitors
TargetsApoptosis regulator Bcl-XInduced myeloid leukemia cell differentiation protein Mcl-1Apoptosis regulator Bcl-2
Therapy Area/IndicationsProstatic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesSanford-Burnham Medical Research InstituteVirginia Commonwealth University
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSeagen IncFortress Biotech IncVirginia Commonwealth University +[4] 
Active IndicationsN/A
Inactive IndicationsProstatic Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A